Phase
Condition
Rash
Warts
Rosacea
Treatment
N/AClinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- A diagnosis of chronic plaque psoriasis (with or without psoriatic arthritis) for atleast 6 months before the first administration of study drug.
- Moderate to severe chronic plaque psoriasis at both Screening and Baseline (Randomization) Visits
- Candidates for systemic therapy or phototherapy for psoriasis treatment as assessed bythe investigator
Exclusion
Exclusion Criteria:
- Prior therapy with an anti-interleukin (IL)-17 or anti-IL12/23p40 or anti-IL-23p19inhibitor
- Concurrent therapy with a biologic and/or other systemic therapy
Study Design
Connect with a study center
GBUZ Interdisctrict Multidisciplinary Hospital
Anzorey, Kabardino-Balkarskaya Respublika 361350
Russian FederationSite Not Available
GBUZ Clinical Dermatovenerology Dispensary of MoH of Krasnodar region /ID# 201713
Krasnodar, Krasnodarskiy Kray 350020
Russian FederationSite Not Available
Family Outpatient clinic#4 LLC /ID# 207441
Korolev, Moskva 141060
Russian FederationSite Not Available
FSBIH ''Siberian District Medical Centre of FMBA of Russia'' /ID# 201898
Novosibirsk, Novosibirskaya Oblast 630007
Russian FederationSite Not Available
LLC ArsVitae Severo-Zapad /ID# 200658
Saint-Petersburg, Sankt-Peterburg 194223
Russian FederationSite Not Available
LLC Kurator /ID# 200616
Saint-Petersburg, Sankt-Peterburg 196240
Russian FederationSite Not Available
SBHI KVD # 10 Clinic of Dermatology and venerology /ID# 200615
Saint-Petersburg, Sankt-Peterburg 194021
Russian FederationSite Not Available
City Clinical Hospital #7 /ID# 200610
Kazan, Tatarstan, Respublika 420103
Russian FederationSite Not Available
Alliance Biomedical Ural Group /ID# 201681
Izhevsk, Udmurtskaya Respublika 426061
Russian FederationSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.